{
  "_links": {
    "self": [
      {
        "href":
          "/preview/GID-NG10186/consultation/113/document/1/chapter-slug/optimum-intervals-for-chronic-open-angle-glaucoma-3"
      }
    ]
  },
  "ETag": "01000000-0000-001A-0000-000000000006",
  "Title": "8.3.2 Optimum intervals for chronic open-angle glaucoma",
  "Slug": "optimum-intervals-for-chronic-open-angle-glaucoma-3",
  "ConsultationId": 113,
  "ConsultationDocumentId": 1,
  "Reference": "GID-NG10186",
  "Content": "<div class=\"chapter\" title=\"8.3.2 Optimum intervals for chronic open-angle glaucoma\" xmlns=\"http://www.w3.org/1999/xhtml\">\r\n  <h2 class=\"title\">\r\n    <a id=\"optimum-intervals-for-chronic-open-angle-glaucoma-3\" style=\"position:relative\" class=\"annotator-chapter\" data-heading-type=\"chapter\" title=\"Comment on chapter\" xmlns=\"\">8.3.2 Optimum intervals for chronic open-angle glaucoma<span class=\"annotator-adder\" /></a>\r\n  </h2>\r\n  <p>No relevant clinical studies were identified.</p>\r\n  <div class=\"section\" title=\"8.4 Overview of Treatment\">\r\n    <h3 class=\"title\">\r\n      <a id=\"overview-of-treatment-3\" style=\"position:relative\" class=\"annotator-chapter\" data-heading-type=\"section\" title=\"Comment on section\" xmlns=\"\">8.4 Overview of Treatment<span class=\"annotator-adder\" /></a>\r\n    </h3>\r\n    <p>Table 2: Any treatment vs. no treatment</p>\r\n    <div class=\"informaltable\">\r\n      <table border=\"1\">\r\n        <colgroup>\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n        </colgroup>\r\n        <tbody>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Study</p>\r\n              <p> details</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Patients </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Interventions</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Outcome measures</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Effect size</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Comments</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td rowspan=\"10\" align=\"left\" valign=\"top\">\r\n              <p>Kass et al., 2002<sup>312</sup></p>\r\n              <p></p>\r\n              <p>Ocular Hypertension Treatment Study (OHTS)</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Study design:</strong>\r\n              </p>\r\n              <p>RCT</p>\r\n              <p>Single masked</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Evidence level:</strong>\r\n              </p>\r\n              <p>1+</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Duration of follow-up:</strong>\r\n              </p>\r\n              <p>Median follow-up for African American participants 72 months and 78 months for other participants.</p>\r\n              <p></p>\r\n            </td>\r\n            <td rowspan=\"10\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Patient group: </strong>OHT patients</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Inclusion criteria: </strong>\r\n              </p>\r\n              <p>Age between 40-80 years, a qualifying IOP between 24 mmHg and 32 mmHg in one eye and between 21 mmHg and 32 mmHg in the other eye, gonioscopically open angles, 2 normal and reliable visual field tests per eye and normal optic discs </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Exclusion criteria:</strong>\r\n              </p>\r\n              <p>Visual acuity worse than 20/40 in either eye, previous intraocular surgery (other than uncomplicated cataract extraction with posterior chamber lens implantation), and diabetic retinopathy or other diseases capable of causing visual field loss or optic disc deterioration. </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Setting</strong>: 22 clinical centres, USA</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>All patients</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 1636    </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong>     817</p>\r\n              <p>\r\n                <strong>N medication withdrawn</strong>:40</p>\r\n              <p>\r\n                <strong>M/F:</strong> 359/458</p>\r\n              <p>\r\n                <strong>Age categories:</strong>\r\n              </p>\r\n              <p>40 to ≤ 50 years: 291 (35.6%) </p>\r\n              <p>&gt;50 to ≤ 60 years: 270 (33.0%)</p>\r\n              <p>&gt;60 to ≤ 70 years: 202 (24.7%)</p>\r\n              <p>&gt;70 to 80 years: 64 (6.6%)</p>\r\n              <p>\r\n                <strong>Previous use of OHT medication</strong>: 35.0%</p>\r\n              <p>\r\n                <strong>First-degree family history of glaucoma</strong>: 34.0%</p>\r\n              <p>\r\n                <strong>Myopia ≥1-diopter spherical equivalent</strong>: 34.4%</p>\r\n              <p>\r\n                <strong>Oral B-adrenergic antagonist</strong>: 5.4%</p>\r\n              <p>\r\n                <strong>Oral calcium channel blocker</strong>: 12.8%</p>\r\n              <p>\r\n                <strong>History of migraine</strong>: 10.4%</p>\r\n              <p>\r\n                <strong>History of diabetes</strong>: 11.5%</p>\r\n              <p>\r\n                <strong>History of hyperte</strong>nsion: 37.5%</p>\r\n              <p>\r\n                <strong>History of low blood pressure</strong>: 4.8%</p>\r\n              <p>\r\n                <strong>History of cardiovascular disease</strong>: 6.8%</p>\r\n              <p>\r\n                <strong>History of stroke</strong>:0.9%</p>\r\n              <p>\r\n                <strong>Drop outs:</strong> 115 (28 died)</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong>     819</p>\r\n              <p>\r\n                <strong>N medication initiated</strong>:42</p>\r\n              <p>\r\n                <strong>M/F:</strong> 346/473</p>\r\n              <p>\r\n                <strong>Age categories:</strong>\r\n              </p>\r\n              <p>40 to ≤ 50 years: 287 (35.0%) </p>\r\n              <p>&gt;50 to ≤ 60 years: 259 (31.6%)</p>\r\n              <p>&gt;60 to ≤ 70 years: 210 (25.6%)</p>\r\n              <p>&gt;70 to 80 years: 63 (7.7%)</p>\r\n              <p>\r\n                <strong>Previous use of OHT medication</strong>: 39.3%</p>\r\n              <p>\r\n                <strong>First-degree family history of glaucoma</strong>: 35.6%</p>\r\n              <p>\r\n                <strong>Myopia ≥1-diopter spherical equivalent</strong>: 33.7%</p>\r\n              <p>\r\n                <strong>Oral B-adrenergic antagonist</strong>: 4.6%</p>\r\n              <p>\r\n                <strong>Oral calcium channel blocker</strong>: 14.0%</p>\r\n              <p>\r\n                <strong>History of migraine</strong>: 11.7%</p>\r\n              <p>\r\n                <strong>History of diabetes</strong>: 12.1%</p>\r\n              <p>\r\n                <strong>History of hypertension</strong>: 38.1%</p>\r\n              <p>\r\n                <strong>History of low blood pressure</strong>: 4.0%</p>\r\n              <p>\r\n                <strong>History of cardiovascular disease</strong>: 6.5%</p>\r\n              <p>\r\n                <strong>History of stroke</strong>: 1.6%</p>\r\n              <p>\r\n                <strong>Drop outs:</strong> 113 (29 died)</p>\r\n            </td>\r\n            <td rowspan=\"10\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>Topical ocular hypotensive medication.</p>\r\n              <p>Treatment to achieve a target IOP of 24 mm Hg or less and a minimum 20% reduction in IOP from the average of the qualifying IOP and IOP at the baseline randomisation visit. Topical medication was changed and/or added until both of these goals were met or the participant was receiving maximum tolerated topical medical therapy. Medications were added and changed in one-eyed therapeutic trials. </p>\r\n              <p></p>\r\n              <p>Included all topical ocular hypotensive medications commercially available in the US. Follow-up visits every six months.</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2<br /><!--[I] - Information: Soft return used in paragraph--></strong>No treatment</p>\r\n              <p></p>\r\n              <p></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Patients developed POAG </strong>(end points of visual field abnormality or optic disc deterioration)</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group1:</strong> 36/817 (4.4%)</p>\r\n              <p>African American: 14/203</p>\r\n              <p>Other: 22/614</p>\r\n              <p>\r\n                <strong>Group 2:</strong> 89/819 (10.9%)</p>\r\n              <p>African American: 26/205</p>\r\n              <p>Other: 63/614</p>\r\n            </td>\r\n            <td rowspan=\"10\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Funding:</strong>\r\n                <br />Study was supported by grants EY09341 and EY09307 from the National Eye Institute and the National Centre on Minority Health and Health Disparities, National Institutes of Health, Bethesda, Md; Merck Research Laboratories, White House Station, NJ; and by an unrestricted grant from Research to Prevent Blindness, New York, NY.<!--[I] - Information: Soft return used in paragraph--></p>\r\n              <p>\r\n                <br />\r\n                <!--[I] - Information: Soft return used in paragraph-->\r\n                <strong>Limitations:</strong>\r\n              </p>\r\n              <p>Patient and clinician were not blinded to randomisation during follow-up.</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Additional outcomes:</strong>\r\n              </p>\r\n              <p>Cumulative probability of developing a reproducible visual field abnormality or an optic disc deteriorations due to POAG or a variety of other caused was reported. </p>\r\n              <p>Estimated of the effect of treatment after adjusting. </p>\r\n              <p>Treatment benefit for reproducible visual field abnormality attributed to POAG and for reproducible optic disc deterioration attributed to POAG reported. </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Notes:</strong>\r\n              </p>\r\n              <p>Randomisation method was adequate and primary outcome assessment was masked. 3328 screened but 1636 entered into study (1692 not eligible for various reasons). </p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Cumulative probability of developing POAG </strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Hazard Ratio: </strong>0.40 </p>\r\n              <p>(95% CI: 0.27 to 0.59)</p>\r\n              <p>\r\n                <strong>p value:</strong> &lt;0.0001</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Cumulative probability of developing POAG at 60 months:</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group1:</strong> 4.4%</p>\r\n              <p>\r\n                <strong>Group 2:</strong> 9.5%</p>\r\n              <p />\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Cumulative probability of developing POAG </strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>African-American participants:</strong>\r\n              </p>\r\n              <p>Hazard ratio: 0.54 (95% CI:0.28-1.03</p>\r\n              <p>\r\n                <strong>Other participants:</strong>\r\n              </p>\r\n              <p>Hazard ratio: 0.34 (95% CI:0.21-0.56</p>\r\n              <p>P=0.26</p>\r\n              <p></p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Change in IOP</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1:</strong>\r\n              </p>\r\n              <p>Baseline: 24.9±2.6</p>\r\n              <p>Reduction from baseline: -22.4%±9.9</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2:</strong>\r\n              </p>\r\n              <p>Baseline: 24.9±2.7</p>\r\n              <p>Reduction from baseline: -4.0%±11.6</p>\r\n              <p></p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Adverse effects:</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Ocular symptoms:</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Group1:</strong> 57%</p>\r\n              <p>\r\n                <strong>Group 2:</strong> 47%</p>\r\n              <p>\r\n                <strong>P</strong>\r\n                <strong>value</strong>: &lt;0.001</p>\r\n              <p>\r\n                <strong>Symptoms affecting skin, hair or nails:</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Group1:</strong> 23%</p>\r\n              <p>\r\n                <strong>Group 2:</strong> 18%</p>\r\n              <p>\r\n                <strong>P</strong>\r\n                <strong>value</strong>: &lt;0.001</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Difference between groups total hospitalisations </strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>P=0.56</strong>\r\n              </p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Difference between groups worsening of pre-existing conditions</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>P=0.28</strong>\r\n              </p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Difference between groups mortality rates</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>P=0.70</strong>\r\n              </p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Other adverse events (</strong>≥<strong>10%)</strong></p>\r\n              <p>\r\n                <strong>Tearing/watering</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Itching</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Blurry or dim vision</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Feels like object in eye</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Poor night vision</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Difficulty Sleeping</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Headache</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Loss of libido</strong>\r\n              </p>\r\n              <p>\r\n                <strong>Numbness/tingling arms</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Medication (%)      Observation (%)</strong>\r\n              </p>\r\n              <p>\r\n                <strong>13.2</strong>\r\n              </p>\r\n              <p>\r\n                <strong>11.8</strong>\r\n              </p>\r\n              <p>\r\n                <strong>11.6</strong>\r\n              </p>\r\n              <p>\r\n                <strong>10.6</strong>\r\n              </p>\r\n              <p>\r\n                <strong>11.8</strong>\r\n              </p>\r\n              <p>\r\n                <strong>16.8</strong>\r\n              </p>\r\n              <p>\r\n                <strong>11.8</strong>\r\n              </p>\r\n              <p>\r\n                <strong>12.6</strong>\r\n              </p>\r\n              <p>\r\n                <strong>13.9                            16.3</strong>\r\n              </p>\r\n            </td>\r\n          </tr>\r\n        </tbody>\r\n      </table>\r\n    </div>\r\n    <p>\r\n      <strong>Abbreviations</strong>:NR=not reported, M/F=male/female, NA=not applicable, N=total number of patients randomised, SD=Standard Deviation, CI95%= 95% Confidence Interval, ITT=Intention to Treat<!--[W] - Warning: Paragraph indentation has been set manually and is different from the paragraph's style--></p>\r\n    <p>\r\n      <br />\r\n      <!--[I] - Information: Soft return used in paragraph-->\r\n      <strong>Any treatment vs. no treatment (continued)</strong>\r\n      <!--[W] - Warning: Paragraph indentation has been set manually and is different from the paragraph's style-->\r\n    </p>\r\n    <div class=\"informaltable\">\r\n      <table border=\"1\">\r\n        <colgroup>\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n        </colgroup>\r\n        <tbody>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Study</p>\r\n              <p> details</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Patients </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Interventions</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Outcome measures</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Effect size</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Comments</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td rowspan=\"6\" align=\"left\" valign=\"top\">\r\n              <p>Heijl et al., 2002<sup>264</sup></p>\r\n              <p>Early Manifest Glaucoma Trial (EMGT)</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Study design:</strong>\r\n              </p>\r\n              <p>RCT</p>\r\n              <p>Single masked</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Evidence level:</strong>\r\n              </p>\r\n              <p>1+</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Duration of follow-up:</strong>\r\n              </p>\r\n              <p>At least 6 years.</p>\r\n              <p></p>\r\n              <p>Open label design but outcome measurement was masked</p>\r\n              <p></p>\r\n            </td>\r\n            <td rowspan=\"6\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Patient group: </strong>patients with chronic open angle glaucoma</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Inclusion criteria: </strong>\r\n              </p>\r\n              <p>Men and women with newly diagnosed, previously untreated COAG (POAG, NTG or PEX) with repeatable visual field defects in at least one eye measured using Humphrey 24-2 full programme. Age between 50 and 80 years</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Exclusion criteria:</strong>\r\n              </p>\r\n              <div class=\"itemizedlist\">\r\n                <ul class=\"itemizedlist\">\r\n                  <li class=\"listitem\">\r\n                    <p>Advanced visual field defects (MD-16dB or threat to fixation)</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Visual acuity &lt; 0.5</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Mean IOP &gt;30 mmHg</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Lens opacities exceeding N1, C1 or P1 in Lens Opacities Classification System</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Patients with glaucomatous visual field defects in both eyes eligible if MD = -10 dB or better in one eye and -16 dB in other eye.</p>\r\n                  </li>\r\n                </ul>\r\n              </div>\r\n              <p></p>\r\n              <p>\r\n                <strong>Setting</strong>: 2 clinical centres (1 reading and 1 co-ordinating), Sweden</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>All patients</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 255    </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 129</p>\r\n              <p>\r\n                <strong>Both eyes eligible</strong>: 34 (26%)</p>\r\n              <p>\r\n                <strong>One eye eligible</strong>: 95 (74%)</p>\r\n              <p>\r\n                <strong>Age ± SD: </strong>68.2 ± 4.8 (range 58-78)</p>\r\n              <p>\r\n                <strong>M/F:</strong> 47/82</p>\r\n              <p>\r\n                <strong>Mean Baseline IOP mmHg ± SD</strong>: 20.6 ± 4.1</p>\r\n              <p>\r\n                <strong>Patients with IOP &lt; 21 mmHg</strong>: 69 </p>\r\n              <p>\r\n                <strong>Mean Visual Acuity</strong>: ± SD: 0.9 ± 0.1</p>\r\n              <p>\r\n                <strong>Mean deviation ± SD</strong>: -5.0 ± 3.7 dB</p>\r\n              <p>\r\n                <strong>Number of optic disc abnormalities (cupping, notching, haemorrhage):</strong> 147</p>\r\n              <p>\r\n                <strong>Myopia 1-diopter spherical equivalent</strong>: 19(12%)</p>\r\n              <p>\r\n                <strong>Exfoliation Syndrome</strong>: 9 (6%)</p>\r\n              <p>Disease History:</p>\r\n              <p>\r\n                <strong>Family history of glaucoma</strong>: 26 (20%)</p>\r\n              <p>34.4%</p>\r\n              <p>\r\n                <strong>Cardiovascular disease</strong>: 19 (15%)</p>\r\n              <p>\r\n                <strong>Stoke/low blood pressure</strong>: 12 (9%)</p>\r\n              <p>\r\n                <strong>General arteriosclerosis</strong>: 4 (3%)</p>\r\n              <p>\r\n                <strong>Peripheral vasospasms and migraine</strong>: 21 (16%)</p>\r\n              <p>\r\n                <strong>Pulmonary disease</strong>: 3 (2%)</p>\r\n              <p>\r\n                <strong>Diabetes</strong>: 3 (2%)</p>\r\n              <p>Medication use:</p>\r\n              <p>\r\n                <strong>Antihypertensives</strong>: 31 (24%)</p>\r\n              <p>\r\n                <strong>Corticosteroids</strong>: 0</p>\r\n              <p>\r\n                <strong>Insulin or oestrogen</strong>: 57 (44%)</p>\r\n              <p>\r\n                <strong>Drop outs:</strong> 24 (3 lost to follow up, 15 died, 6 received ALT but discontinued medications)</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 126</p>\r\n              <p>\r\n                <strong>Both eyes eligible</strong>: 27 (21%)</p>\r\n              <p>\r\n                <strong>One eye eligible</strong>: 99 (79%)</p>\r\n              <p>\r\n                <strong>Age ± SD: </strong>68.0 ± 5.0 (range 50-79)</p>\r\n              <p>\r\n                <strong>M/F:</strong> 39/87</p>\r\n              <p>\r\n                <strong>Mean Baseline IOP mmHg ± SD</strong>: 20.9 ± 4.1</p>\r\n              <p>\r\n                <strong>Patients with IOP &lt; 21 mmHg</strong>: 63 </p>\r\n              <p>\r\n                <strong>Mean Visual Acuity</strong>: ± SD: 1.0 ± 0.1</p>\r\n              <p>\r\n                <strong>Mean deviation ± SD</strong>: -4.4 ± 3.3 dB</p>\r\n              <p>\r\n                <strong>Number of optic disc abnormalities (cupping, notching, haemorrhage):</strong> 138</p>\r\n              <p>\r\n                <strong>Myopia 1-diopter spherical equivalent</strong>: 23(15%)</p>\r\n              <p>\r\n                <strong>Exfoliation Syndrome</strong>: 16 (10%)</p>\r\n              <p>Disease History:</p>\r\n              <p>\r\n                <strong>Family history of glaucoma</strong>: 24 (19%)</p>\r\n              <p>34.4%</p>\r\n              <p>\r\n                <strong>Cardiovascular disease</strong>: 14 (11%)</p>\r\n              <p>\r\n                <strong>Stoke/low blood pressure</strong>: 5 (4%)</p>\r\n              <p>\r\n                <strong>General atheriosclerosis</strong>: 5 (4%)</p>\r\n              <p>\r\n                <strong>Peripheral vasospasms and migraine</strong>: 26 (21%)</p>\r\n              <p>\r\n                <strong>Pulmonary disease</strong>: 0</p>\r\n              <p>\r\n                <strong>Diabetes</strong>: 6 (5%)</p>\r\n              <p>Medication use:</p>\r\n              <p>\r\n                <strong>Antihypertensives</strong>: 31 (25%)</p>\r\n              <p>\r\n                <strong>Corticosteroids</strong>: 4 (3%)</p>\r\n              <p>\r\n                <strong>Insulin or oestrogen</strong>: 55 (44%)</p>\r\n              <p>\r\n                <strong>Drop outs:</strong> 10 (3 lost to follow up, 7 died)</p>\r\n            </td>\r\n            <td rowspan=\"6\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>Betaxolol 5 mg/ml 2/day and argon laser trabeculoplasty (ALT) 360 degrees performed 1 week after inclusion.</p>\r\n              <p>If eligible eye achieved 25 mmHg in 2 consecutive visits or other eye was 35 mmHg in 1 visit then latanoprost 50 m/day.</p>\r\n              <p></p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2<br /><!--[I] - Information: Soft return used in paragraph--></strong>No treatment</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Examination methods:</strong>\r\n              </p>\r\n              <p>Patients were followed up at 3 month intervals for visual acuity, Goldmann tonometry, Humphrey 30-2 Full threshold visual field testing, ophthalmoscopy, slit lamp examination and optic disc photographs every 6 months.</p>\r\n              <p></p>\r\n              <p>*Visual field progression defined as worsening of 3 consecutive points in the Glaucoma Change Probability map, confirmed by 3 consecutive visual fields.</p>\r\n              <p></p>\r\n              <p>*Optic disc progression detected from baseline line and follow up photographs by a masked reader using flicker chronoscopy and </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Glaucoma progression (visual or optic disc changed*) after follow up of 48 months</strong>\r\n              </p>\r\n              <p>Data from Rolim et al., 2007<sup>571</sup></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 39/129 (30%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 62/126 (49%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.002 (calculated by NCC-AC Chi-squared test)</p>\r\n              <p></p>\r\n            </td>\r\n            <td rowspan=\"6\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Funding:</strong>\r\n                <br />Study was supported by grants U10EY10260 and U10EY10261 from the National Eye Institute, <!--[I] - Information: Soft return used in paragraph-->Bethesda, USA and K2002-74X-10426-10A from the Swedish Research Council, Stockholm</p>\r\n              <p>\r\n                <br />\r\n                <!--[I] - Information: Soft return used in paragraph-->\r\n                <strong>Limitations:</strong>\r\n              </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Additional outcomes:</strong>\r\n              </p>\r\n              <p>Health-related quality of life scores</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Notes:</strong>\r\n              </p>\r\n              <p>Randomised using computer generated sequence. Computerised visual field and optic disc photographs read by masked observers. IOP evaluation also masked.</p>\r\n              <p>An Intention to Treat analysis was used.</p>\r\n              <p></p>\r\n              <p>Patients and clinicians were not masked to treatment allocation</p>\r\n              <p></p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Glaucoma progression (visual field and optic disc) after 6 years (range 51-102 months</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 58/129 (45%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 78/126 (62%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.07</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Visual field progression alone  after 6 years (range 51-102 months</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 57/129 (44%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 78/126 (62%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.005 (calculated by NCC-AC Chi-squared test)</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Ocular side effects (reduction in visual acuity, floaters or conjunctivitis)</strong>\r\n              </p>\r\n              <p></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 21/129 (16%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 16/126 (13%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.43 (calculated by NCC-AC Chi-squared test)</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Systemic side effects (asthma, bradycardia, depression)</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 6/129 (4.6%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 1/126 (0.8%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.12 (calculated by NCC-AC Fishers exact test)</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p></p>\r\n            </td>\r\n          </tr>\r\n        </tbody>\r\n      </table>\r\n    </div>\r\n    <p>\r\n      <strong>Abbreviations</strong>:NR=not reported, M/F=male/female, NA=not applicable, N=total number of patients randomised, SD=Standard Deviation, CI95%= 95% Confidence Interval, ITT=Intention to Treat <!--[W] - Warning: Paragraph indentation has been set manually and is different from the paragraph's style--></p>\r\n    <p>\r\n      <br />\r\n      <!--[I] - Information: Soft return used in paragraph-->\r\n      <strong>Any treatment vs. no treatment (continued)</strong>\r\n      <!--[W] - Warning: Paragraph indentation has been set manually and is different from the paragraph's style-->\r\n    </p>\r\n    <div class=\"informaltable\">\r\n      <table border=\"1\">\r\n        <colgroup>\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n          <col />\r\n        </colgroup>\r\n        <tbody>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Study</p>\r\n              <p> details</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Patients </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Interventions</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Outcome measures</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Effect size</p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>Comments</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td rowspan=\"4\" align=\"left\" valign=\"top\">\r\n              <p>Collaborative Normal-Tension Glaucoma Study Group, 1998<sup>136</sup></p>\r\n              <p></p>\r\n              <p>Collaborative Normal-Tension Glaucoma Study (CNTGS)</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Study design:</strong>\r\n              </p>\r\n              <p>RCT</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Evidence level:</strong>\r\n              </p>\r\n              <p>1+</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Duration of follow-up:</strong>\r\n              </p>\r\n              <p>5 years.</p>\r\n              <p></p>\r\n            </td>\r\n            <td rowspan=\"4\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Patient Group: </strong>Normal tension glaucoma</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Inclusion criteria: </strong>\r\n              </p>\r\n              <p>Unilateral or bilateral normal tension glaucoma with optic disc abnormalities and visual field defects and IOP  24 mmHg in either eye. Age 20 to 90 years. After 4 week washout patients required to have a median of 10 IOP readings of  20 mmHg and 3 good baseline visual fields.</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Exclusion criteria:</strong>\r\n              </p>\r\n              <div class=\"itemizedlist\">\r\n                <ul class=\"itemizedlist\">\r\n                  <li class=\"listitem\">\r\n                    <p>Patients on systemic beta-blockers or clonidine.</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Patients unable to perform visual field test</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Eyes with previous laser treatment, ocular surgery </p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Eyes with traumatic VF defects</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Narrow angles</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Best correct visual acuity of &lt; 20/30</p>\r\n                  </li>\r\n                  <li class=\"listitem\">\r\n                    <p>Baseline visual fields too damaged to record further progression</p>\r\n                  </li>\r\n                </ul>\r\n              </div>\r\n              <p></p>\r\n              <p>\r\n                <strong>Setting</strong>: 24 clinical centres, international</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>All patients</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 145</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 79</p>\r\n              <p>\r\n                <strong>Age ± SD: </strong>65.5 ± 9.6</p>\r\n              <p>\r\n                <strong>M/F:</strong> 30/49</p>\r\n              <p>\r\n                <strong>Mean IOP at randomisation mmHg ± SD</strong>: 16.1 ± 2.3</p>\r\n              <p>\r\n                <strong>Visual Acuity</strong>: 0.89 ± 2.86</p>\r\n              <p>\r\n                <strong>Mean deviation at randomisation ± SD</strong>: </p>\r\n              <p>-7.54 ± 4.31 dB</p>\r\n              <p>\r\n                <strong>Refraction</strong>: -0.66 ± 2.86</p>\r\n              <p>Ethnicity</p>\r\n              <p>\r\n                <strong>Asian</strong>: 9</p>\r\n              <p>\r\n                <strong>Black</strong>: 2</p>\r\n              <p>\r\n                <strong>Hispanic</strong>: 2</p>\r\n              <p>\r\n                <strong>White</strong>: 65</p>\r\n              <p>\r\n                <strong>Drop outs:</strong> 5</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2</strong>\r\n              </p>\r\n              <p>\r\n                <strong>N:</strong> 61</p>\r\n              <p>\r\n                <strong>Age ± SD: </strong>66.3 ± 10.3</p>\r\n              <p>\r\n                <strong>M/F:</strong> 17/44</p>\r\n              <p>\r\n                <strong>Mean IOP at randomisation mmHg ± SD</strong>: 16.9 ± 2.1</p>\r\n              <p>\r\n                <strong>Visual Acuity</strong>: 0.89 ± 0.15</p>\r\n              <p>\r\n                <strong>Mean deviation at randomisation ± SD</strong>: </p>\r\n              <p>-8.38 ± 5.26 dB</p>\r\n              <p>\r\n                <strong>Refraction</strong>: -1.09 ± 3.3</p>\r\n              <p>Ethnicity</p>\r\n              <p>\r\n                <strong>Asian</strong>: 3</p>\r\n              <p>\r\n                <strong>Black</strong>: 5</p>\r\n              <p>\r\n                <strong>Hispanic</strong>: 1</p>\r\n              <p>\r\n                <strong>White</strong>: 51</p>\r\n              <p>\r\n                <strong>Drop outs:</strong>\r\n              </p>\r\n            </td>\r\n            <td rowspan=\"4\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>\r\n              </p>\r\n              <p>Achieved 30% change in IOP using medical or surgical interventions except for beta-blockers or adrenergic agonists. </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Group 2<br /><!--[I] - Information: Soft return used in paragraph--></strong>No treatment</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Examination methods:</strong>\r\n              </p>\r\n              <p>Patients were followed up at 3 month intervals for first year and every 6 months thereafter. </p>\r\n              <p>Tests performed for visual acuity, visual field using Humphrey and appearance of optic disc and optic disc photographs every year.</p>\r\n              <p></p>\r\n              <p>Visual field progression was defined by deepening of existing scotoma, expansion of an existing scotoma or new or expanded threat to fixation (cluster of 3 points) or fresh scotoma in previously normal part of visual field. </p>\r\n              <p>*Visual field progression was confirmed by 4/5 consecutive follow up visits showed progression relative to baseline.</p>\r\n              <p></p>\r\n              <p>Optic disc damage was independently assesses by masked observers using stereo photographs and agreed. </p>\r\n              <p></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Glaucoma progression  (optic disc or visual field progression*)</strong>\r\n              </p>\r\n              <p>Data from Sycha et al., 2003<sup>644</sup></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 22/61 (31%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 31/79 (39%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.7 (calculated by NCC-AC Chi-squared test)</p>\r\n              <p></p>\r\n            </td>\r\n            <td rowspan=\"4\" align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Funding:</strong>\r\n                <br />Glaucoma research Foundation with grants from Oxnard Foundation and Edward J Daly Foundation, <!--[I] - Information: Soft return used in paragraph-->San Francisco</p>\r\n              <p>\r\n                <br />\r\n                <!--[I] - Information: Soft return used in paragraph-->\r\n                <strong>Limitations:</strong>\r\n              </p>\r\n              <p>Allocation concealment and masking of outcome assessment was not clearly reported</p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Additional outcomes:</strong>\r\n              </p>\r\n              <p></p>\r\n              <p>\r\n                <strong>Notes:</strong>\r\n              </p>\r\n              <p>Randomisation using block randomisation scheme occurred after selected eye had a visual field defect that threatened fixation.</p>\r\n              <p></p>\r\n              <p>Intention to treat analysis was performed</p>\r\n              <p></p>\r\n              <p>The study was carried out before the introduction of topical carbonic anhydrase inhibitors and prostaglandin analogues.</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Visual Field Progression*</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 11/61 (18%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 24/79 (30%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.09 (calculated by NCC-AC Chi-squared test)</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Cataract Formation</strong>\r\n              </p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p>\r\n                <strong>Group 1</strong>: 23/61 (38%)</p>\r\n              <p>\r\n                <strong>Group 2</strong>: 11/79 (14%)</p>\r\n              <p>\r\n                <strong>p value</strong>: 0.011 (calculated by NCC-AC Chi-squared test)</p>\r\n            </td>\r\n          </tr>\r\n          <tr>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p></p>\r\n            </td>\r\n            <td align=\"left\" valign=\"top\">\r\n              <p></p>\r\n            </td>\r\n          </tr>\r\n        </tbody>\r\n      </table>\r\n    </div>\r\n    <p>\r\n      <strong>Abbreviations</strong>:NR=not reported, M/F=male/female, NA=not applicable, N=total number of patients randomised, SD=Standard Deviation, CI95%= 95% Confidence Interval, ITT=Intention to Treat<!--[W] - Warning: Paragraph indentation has been set manually and is different from the paragraph's style--></p>\r\n  </div>\r\n  <div class=\"section\" title=\"8.5 Treatment of ocular hypertension, suspected chronic open-angle glaucoma and chronic open-angle glaucoma\">\r\n    <h3 class=\"title\">\r\n      <a id=\"treatment-of-ocular-hypertension-suspected-chronic-open-angle-glaucoma-and-chronic-open-angle-3\" style=\"position:relative\" class=\"annotator-chapter\" data-heading-type=\"section\" title=\"Comment on section\" xmlns=\"\">8.5 Treatment of ocular hypertension, suspected chronic open-angle glaucoma and chronic open-angle glaucoma<span class=\"annotator-adder\" /></a>\r\n    </h3>\r\n  </div>\r\n</div>",
  "Sections": [
    { "Slug": "overview-of-treatment-3", "Title": "8.4 Overview of Treatment" },
    {
      "Slug":
        "treatment-of-ocular-hypertension-suspected-chronic-open-angle-glaucoma-and-chronic-open-angle-3",
      "Title":
        "8.5 Treatment of ocular hypertension, suspected chronic open-angle glaucoma and chronic open-angle glaucoma"
    }
  ]
}
